These results are compatible with previous studies using different methods for HER2 detection [13–15] and further support the already described discordance of HER2 status between the primary tumors and the corresponding CTCs, both in patients with early and metastatic disease [13, 28]. The gene discussed is ERBB2; the disease is metastatic neoplasm.